PrEP Descovy Oral denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for prep descovy oral are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Descovy for PrEP as "Experimental" — and Why You Can Appeal

Descovy (emtricitabine/tenofovir alafenamide) is FDA-approved specifically for pre-exposure prophylaxis (PrEP) for HIV prevention in at-risk adults and adolescents who are HIV-negative. An "experimental or investigational" denial for an FDA-approved indication is a serious claims-processing error, and it is one of the most successfully overturned denial types on appeal.

This denial most commonly occurs in one of two scenarios: (1) a claims-editing system misclassified the submitted diagnosis or procedure code, triggering an experimental flag; or (2) the denial was generated under an outdated policy predating Descovy's PrEP approval. Either way, the clinical and regulatory record strongly supports reversal.

### Why This Is Appealable

FDA approval establishes that a drug is safe and effective for its labeled indication. An insurer cannot override FDA approval by labeling an approved use "experimental." Additionally, the ACA's preventive-services mandate requires coverage of PrEP medications rated by the USPSTF without cost-sharing for qualifying individuals. Denying an FDA-approved PrEP drug as experimental potentially violates both principles simultaneously.

### Your Federal Appeal Rights

• Internal appeal: Under ERISA §503 or ACA §2719, you have the right to a full and fair internal review within the deadline on your denial notice.
• External review: After a final internal denial, request IRO review within the four-month window under ACA §2719. An external reviewer applying accepted medical standards will almost certainly find that Descovy for PrEP is not experimental.
• Expedited review: If delay would seriously jeopardize your health, an expedited decision is typically required within 72 hours.

### Documentation to Gather

1. FDA approval documentation — download the current FDA label from DailyMed confirming the approved PrEP indication. This is the single most important document in the appeal. 2. USPSTF PrEP recommendation — cite the USPSTF Grade A recommendation for PrEP generically (organization and grade, not numeric details) as evidence of accepted medical practice. 3. Prescriber letter — confirming the patient is HIV-negative, meets criteria for PrEP per current clinical guidelines, and that Descovy is prescribed for its FDA-approved PrEP indication. 4. UHC's experimental/investigational policy — request the specific policy used to deny. Identify any criterion that conflicts with the FDA approval record and address it point by point. 5. Coding verification — confirm with the prescriber's office that the submitted diagnosis and procedure codes correctly reflect the PrEP indication; a coding correction alone may resolve the denial.

### Criteria-Mapping Structure

List each experimental/investigational criterion from UHC's policy in a table. In the right column, show how the FDA approval, USPSTF recommendation, and clinical record satisfy — or refute — each criterion. Lead with the FDA label: if UHC's own definition of "non-experimental" requires FDA approval, the appeal is resolved on that point alone.

### Next Step

Request the complete explanation of benefits and the specific UHC medical policy cited in the denial before drafting your appeal. If the denial letter cites an outdated policy or a policy that does not reference the PrEP indication, that discrepancy should be the opening argument of your appeal letter.